506331662 10/30/2020

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6378413

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
THOMAS JORG MEHRLING	06/07/2018

RECEIVING PARTY DATA

Name:	MUNDIPHARMA EDO GMBH	
Street Address:	ST. ALBAN RHEINWEG 74	
City:	BASEL	
State/Country:	SWITZERLAND	
Postal Code:	CH-4020	

PROPERTY NUMBERS Total: 4

Property Type	Number
Application Number:	16621885
Application Number:	16621893
Application Number:	16621896
Application Number:	16621898

CORRESPONDENCE DATA

Fax Number: (617)607-9200

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (617) 449-6523

 Email:
 oquiterio@mccarter.com

 Correspondent Name:
 MCCARTER & ENGLISH, LLP

Address Line 1: 265 FRANKLIN STREET

Address Line 4: BOSTON, MASSACHUSETTS 02110

ATTORNEY DOCKET NUMBER:	132179-00301
NAME OF SUBMITTER:	YU LU, PH.D.
SIGNATURE:	/Yu Lu/
DATE SIGNED:	10/30/2020

Total Attachments: 8

source=PPLP 17-ON-0003-Thomas Mehrling to MEDO#page1.tif source=PPLP 17-ON-0003-Thomas Mehrling to MEDO#page2.tif source=PPLP 17-ON-0003-Thomas Mehrling to MEDO#page3.tif

PATENT 506331662 REEL: 054228 FRAME: 0436

source=PPLP 17-ON-0003-Thomas Mehrling to MEDO#page4.tif source=PPLP 17-ON-0003-Thomas Mehrling to MEDO#page5.tif source=PPLP 17-ON-0003-Thomas Mehrling to MEDO#page6.tif source=PPLP 17-ON-0003-Thomas Mehrling to MEDO#page7.tif source=PPLP 17-ON-0003-Thomas Mehrling to MEDO#page8.tif

(1) THOMAS JORG MEHRLING

- and -

(2) MUNDIPHARMA EDO GMBH

ASSIGNMENT OF PATENT APPLICATIONS AND RELATED WORLDWIDE RIGHTS

Ref: MC928087WO

BETWEEN

(1) Thomas Jorg Mehrling, an individual residing at Sevogelstrasse 30, CH-4052 Basel, Switzerland (the "Assignor"); and

(2) Mundipharma EDO GmbH, a Swiss company whose principal place of business is at St. Alban Rheinweg 74, CH-4020 Basel, Switzerland (the "Assignee").

RECITALS

(A) Patent applications ("the Applications") have been filed, further particulars of which are given in the Schedule, in respect of the Inventions respectively disclosed in the Applications ("the Inventions").

(B) The Assignor has agreed to assign to the Assignee the Inventions and the Applications and all his rights, title and interest therein upon the terms and conditions set out below.

OPERATIVE PROVISIONS

 In consideration of the sum of £1 paid by the Assignee to the Assignor (the receipt and sufficiency of which the Assignor hereby acknowledges) the Assignor with full title guarantee HEREBY ASSIGNS unto the Assignee:

(a) the Inventions and the full and exclusive benefit of them;

(b) all the rights of the Assignor in and to the Applications and the full and exclusive benefit of them and all rights privileges and advantages associated with them;

(c) the full right to apply for and obtain patents or other similar forms of protection in respect of the Inventions throughout the world;

- (d) the right to make any new application or applications anywhere in the world in respect of any part or parts of the subject matter of any application or specification filed in connection with the Inventions;
- (e) any patents or other similar forms of protection granted in respect of the Inventions pursuant to the Applications;
- (f) the right to claim priority of the Applications; and
- (g) the right to bring proceedings (anywhere in the world) for the recovery of damages and/or other remedies in respect of any previous infringement of the rights assigned by this Assignment.

TO HOLD the same unto the Assignee absolutely.

- 2. The Assignor warrants that:
 - (a) it has not assigned or licensed any of the rights under the Applications;
 - (b) each Application is free from any security interest, option, mortgage, charge or lien put in place by the Assignor;
 - (c) this assignment and exploitation of the Applications will not infringe the rights of any third party, so far as the Assignor is aware.
- The Assignor undertakes that it will not without the consent of the Assignee publish or disclose any particulars of the Inventions or the Applications to any person.
- 4. The Assignor hereby covenants with the Assignee that it shall execute such further documents and do such further acts, and shall procure on the part of the inventors of the Inventions the execution and doing of all such further documents and acts, as may reasonably be required by the Assignee to enable the Assignee (or its nominee) to enjoy the full benefit of the property and rights hereby assigned and to apply for any patents or other forms of protection in respect of the Inventions throughout the world, and fully and effectively to vest the same in the Assignee or as the Assignee shall direct.

- 5. The Assignor further covenants with the Assignee that at the request and expense of the Assignee it shall provide all such assistance as the Assignee may reasonably require in connection with any proceedings concerning the Applications or any patents, patent applications or similar rights applied for or arising in respect of the Inventions, including the disclosure of relevant documents and materials and the provision of oral and written testimony from relevant personnel.
- 6. This Assignment shall be governed by and construed in accordance with English law and shall be subject to the exclusive jurisdiction of the English courts.

IN WITNESS of which this Assignment has been executed as a Deed and delivered the date and year first above written.

SCHEDULE

Patent Applications

Reference	Application Number	Date Filed	Subject Matter	Designated States (PCT)
PC928106 P1422-GB-1	1709402.0	13-06-2017	Treatment of T-PLL	
P1422-AR-1				
P1422-GC-1		32.00.00		
P1422-PK-1				
P1422-TW-1				
P1422-WO-1				ALL
PC928255 P1437-GB-1	1709403.8	13-06-2017	Compounds for treating sarcoma	
P1437-AR-1				
P1437-GC-1				
P1437-PK-1				
P1437-TW-1				
P1437-WO-1				ALL
PC928271 P1442-GB-1	1709406.1	13-06-2017	Compounds for treating TNBC	
P1442-AR-1				
P1442-GC-1			Z	
P1442-PK-1				
P1442-TW-1				
P1442-WO-1				ALL

PC928257 P1439-GB-1	1709405.3	13-06-2017	Compounds for treating ovarian cancer	
P1439-AR-1				
P1439-GC-1				
P1439-PK-1				
P1439-TW-1				
P1439-WO-1				ALL
PC928187 P1440-GB-1	1709544.9	15-06-2017	Compounds for treating vasculitis	
P1440-AR-1				
P1440-GC-1				
P1440-PK-1				
P1440-TW-1				
P1440-WO-1				ALL
PC928189 P1441-GB-1	1709559.7	15-06-2017	Compounds for treating lupus erythematosus	
P1441-AR-1				
P1441-GC-1				
P1441-PK-1				
P1441-TW-1				
P1441-WO-1				ALL
PC928179 P1436-GB-1	1715404.8	22-9-2017	Improved Process for the Preparation of a	

		Formulation	
P1436-AR-1			
P1436-GC-1			
P1436-PK-1	000 000 1000 		
P1436-TW-1			
P1436-WO-1			ALL

SIGNED as a deed by THOMAS JORG MEHRLING
Signature: Thomas June 5
Date: 2018
In the presence of: Signature of witness:
Signature of wholess.
Name of witness:
Address of witness H. Lilled Jahanna. Colo Jack / Barel
Address of witness H. Linedajahannes Colo Jack Berd Occupation of witness Execusion of witness
Date: J. June 2018
SIGNED as a deed by MUNDIPHARMA EDO GMBH
acting by Thomas Mehrling,
director
Signature:
Date:
T (1)
In the presence of:
Signature of witness: D. J. J. L. J. J. J. J. L. J. J. J. L. J.
Name of witness:
Name of witness: Dafuncy Isunz Address of witness. Humbiphanus Colo fully Basel Occupation of witness. Executive Isona Coloration
Occupation of witness Executive Isome Color divotor
Date: 2018